首页> 外文期刊>Analytical and bioanalytical chemistry >Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis C using serum Fourier transform infrared spectroscopy
【24h】

Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis C using serum Fourier transform infrared spectroscopy

机译:血清傅立叶变换红外光谱法对慢性丙型肝炎患者肝纤维化的无创评估

获取原文
获取原文并翻译 | 示例
           

摘要

Assessment of liver fibrosis is of paramount importance to guide the therapeutic strategy in patients with chronic hepatitis C (CHC). In this pilot study, we investigated the potential of serum Fourier transform infrared (FTIR) spectroscopy for differentiating CHC patients with extensive hepatic fibrosis from those without fibrosis. Twenty-three serum samples from CHC patients were selected according to the degree of hepatic fibrosis as evaluated by the FibroTest: 12 from patients with no hepatic fibrosis (F0) and 11 from patients with extensive fibrosis (F3-F4). The FTIR spectra (ten per sample) were acquired in the transmission mode and data homogeneity was tested by cluster analysis to exclude outliers. After selection of the most discriminant wavelengths using an ANOVA-based algorithm, the support vector machine (SVM) method was used as a supervised classification model to classify the spectra into two classes of hepatic fibrosis, F0 and F3-F4. Given the small number of samples, a leave-one-out cross-validation algorithm was used. When SVM was applied to all spectra (n = 230), the sensitivity and specificity of the classifier were 90.1% and 100%, respectively. When SVM was applied to the subset of 219 spectra, i.e., excluding the outliers, the sensitivity and specificity of the classifier were 95.2% and 100%, respectively. This pilot study strongly suggests that the serum from CHC patients exhibits infrared spectral characteristics, allowing patients with extensive fibrosis to be differentiated from those with no hepatic fibrosis.
机译:评估肝纤维化对于指导慢性丙型肝炎(CHC)患者的治疗策略至关重要。在这项前期研究中,我们研究了血清傅立叶变换红外光谱(FTIR)在区分患有广泛肝纤维化的CHC患者和未发生肝纤维化的CHC患者中的潜力。根据FibroTest评估的肝纤维化程度,从CHC患者中选择了23份血清样本:12例无肝纤维化(F0)患者和11例广泛性纤维化(F3-F4)患者。 FTIR光谱(每个样品10个)以透射模式获取,并通过聚类分析测试数据均匀性,以排除异常值。在使用基于ANOVA的算法选择最能区分的波长后,将支持向量机(SVM)方法用作监督分类模型,以将光谱分为两类肝纤维化,即F0和F3-F4。考虑到样本数量少,使用了留一法交叉验证算法。当将SVM应用于所有光谱(n = 230)时,分类器的灵敏度和特异性分别为90.1%和100%。当将SVM应用到219个光谱的子集(即排除异常值)时,分类器的灵敏度和特异性分别为95.2%和100%。这项初步研究强烈建议,来自CHC患者的血清具有红外光谱特征,可以将广泛纤维化的患者与没有肝纤维化的患者区分开。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号